Verdence Capital Advisors 13F: Adds $3.2M to AbbVie (ABBV) Stake
Key Points
- Verdence Capital Advisors increased its holdings in AbbVie by 12,209 shares, a 44.5% rise, now totaling 39,628 shares.
- AbbVie shares recently traded at about $286.39, slightly below the $286.74 closing price on the filing date.
- The fund's investment in AbbVie represents 1.71% of its total reported value of approximately $604.5 million.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
On October 26, 2026, Verdence Capital Advisors boosted its position in AbbVie Inc. (ABBV) by 12,209 shares, bringing its total to 39,628 shares valued at about $10.37 million. This information comes from the fund's latest Form 13F filing with the SEC.
Verdence Capital Advisors added 12,209 shares, increasing its stake by 44.5%. The total reported value of AbbVie in the fund's portfolio is approximately $10.37 million, representing 1.71% of its total assets. The fund ranks 22nd among its 758 reported positions.
ABBV
AbbVie Inc.
Verdence Capital Advisors vs. the S&P 500
Hypothetical returns from Verdence Capital Advisors's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in AbbVie
UniSuper Management added 86,423 shares of AbbVie, bringing its total to 456,240 shares worth about $119.3 million. Meanwhile, Vest Financial reduced its stake by 43,631 shares, now holding 224,688 shares valued at approximately $58.8 million. AMF Tjanstepension also decreased its holdings by 6,790 shares, ending with 24,119 shares valued at around $6.3 million.
AbbVie Inc. Stock Up 0.3%
AbbVie shares recently traded around $286.39, which is about equal to the $286.74 closing price on October 26, 2026. The stock is above its 50-day moving average by 7.3% and its 200-day moving average by 21.5%. However, it remains below its 52-week high of $291.40 by about 1.7%.
Recent Earnings
For the trailing twelve months, AbbVie reported revenue of approximately $64.4 billion and an EPS of $3.55. The company has a net margin of 9.8% and a year-over-year revenue growth of 10.2%. AbbVie is set to report its next earnings on October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie pays an annual dividend of $6.92 per share, which translates to a yield of 2.41%. The dividend payout ratio is 190.4%, indicating a strong commitment to returning value to shareholders.
Insider Buying and Selling at AbbVie Inc.
Several insiders have sold shares recently, including Perry C. Siatis, General Counsel, who sold 22,381 shares at $230.00 on February 25, 2026. Nicholas Donoghoe, another officer, sold 32,710 shares at $250.00 on August 14, 2026.
Analysts Set New Price Targets
On October 9, 2026, UBS maintained a Neutral rating with a price target of $275. Guggenheim reiterated a Buy rating with a target of $288, while RBC Capital also reiterated an Outperform rating with a target of $280. Barclays maintained an Overweight rating with a target of $325 on October 21, and Goldman Sachs maintained a Neutral rating with a target of $294 on October 23.
About AbbVie
AbbVie Inc. is a biopharmaceutical company based in North Chicago, IL, focused on developing and selling medicines worldwide. Its key products include Skyrizi for autoimmune diseases and Rinvoq for inflammatory conditions, among others. This boost in position reflects the fund's confidence in AbbVie's ongoing growth and product pipeline.
Bottom Line
Investors will be looking for AbbVie's next earnings report on October 30, 2026, to see how the company continues to perform in the competitive healthcare sector. Verdence Capital Advisors has shown a strong commitment to AbbVie, increasing its stake significantly, which may indicate positive expectations for the stock.
Related Filing Alerts
Source: Verdence Capital Advisors's 13F filing on $ABBV (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts